Raymond James Financial Services Advisors’s Denali Therapeutics DNLI Stock Holding History

Raymond James Financial Services Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,252	Closed	-$215K	–	3343
2021 Q3	$215K	Hold	4,252	–	–	﹤0.01%	2929
2021 Q2	$334K	Sell	4,252 -80	-2%	-$4.95K	﹤0.01%	2646
2021 Q1	$247K	Sell	4,332 -400	-8%	-$26.8K	﹤0.01%	2757
2020 Q4	$396K	Buy	+4,732	New	+$286K	﹤0.01%	2285
2019 Q2	–	Sell	-9,588	Closed	-$223K	–	2857
2019 Q1	$223K	Sell	9,588 -475	-5%	-$9.94K	﹤0.01%	2430
2018 Q4	$208K	Sell	10,063 -10,390	-51%	-$188K	﹤0.01%	2237
2018 Q3	$445K	Buy	20,453 +2,200	+12%	+$36.4K	﹤0.01%	2005
2018 Q2	$278K	Buy	+18,253	New	+$344K	﹤0.01%	2288

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Raymond James Financial Services Advisors's DNLI Position: Q4 2021 in Review

Raymond James Financial Services Advisors sold out of Denali Therapeutics (DNLI) in Q4 2021, closing a stake of 4,252 shares — an estimated $215K sold.

Raymond James Financial Services Advisors first reported a position in DNLI in Q2 2018 and held it in 8 quarters. The position peaked at $445K in Q3 2018. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

Raymond James Financial Services Advisors reported no remaining Denali Therapeutics position as of Q4 2021 after selling out during the quarter.
Raymond James Financial Services Advisors sold 4,252 Denali Therapeutics shares in Q4 2021, an estimated $215K.
Raymond James Financial Services Advisors first reported a position in Denali Therapeutics in Q2 2018 and held it in 8 quarters.
Raymond James Financial Services Advisors's Denali Therapeutics position peaked at $445K in Q3 2018.
213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.